Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.52 |
| ▸ | VNN1 | O95497 | 5/20 | 0.43 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.41 |
| ▸ | RXRG | P48443 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | XPO1 | O14980 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593993 | 1.00 | CES2 (0.52) | CES2VNN1RXRARXRBRXRG | |
| SCHEMBL322157 | 0.87 | CES2 (0.67) | CES2RXRARXRBRXRGCES1 | |
| SCHEMBL8703955 | 0.84 | CES2 (0.41) | CES2VNN1RXRARXRBRXRG | |
| SCHEMBL27757817 | 0.83 | CES2 (0.56) | CES2VNN1RXRARXRBRXRG | |
| SCHEMBL8109410 | 0.83 | CES2 (0.43) | CES2VNN1RXRARXRBRXRG | |
| SCHEMBL586089 | 0.82 | HCAR1 (0.55) | CES2VNN1RXRARXRBRXRG | |
| SCHEMBL30770849 | 0.82 | HCAR1 (0.55) | CES2VNN1RXRARXRBRXRG | |
| SCHEMBL1827001 | 0.82 | CES2 (0.54) | CES2VNN1RXRARXRBRXRG | |
| SCHEMBL114867 | 0.80 | CES2 (0.62) | CES2CES1HDAC1HDAC6 | |
| SCHEMBL2293145 | 0.80 | CES2 (0.55) | CES2CES1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553911-B2 | Coated polydivinylbenzene beads | JORDI FLP (US) | 2009-06-30 | — | — | US | claimed |
| US-20080255269-A1 | Polystyrene divinylbenzene copolymer having a fluorinated, amidated surface; high performance liquid chromatography tationary phase | JORDI HOWARD C | 2008-10-16 | — | — | US | claimed |
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12583851-B2 | Heteroaryl-substituted pyrazine derivatives as pesticides | ELANCO ANIMAL HEALTH GMBH (DE) | 2026-03-24 | — | — | US | disclosed |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RELAY THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4585596-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Yingli Pharmaceutical Co., Ltd (CN) | 2025-07-16 | — | — | EP | disclosed |
| CN-120152713-A | Tricyclic aryl derivatives and compositions and methods thereof | 昂胜医疗科技公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4561562-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4561563-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250171444-A1 | PI3Ka INHIBITORS | PIKAVATION THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| CN-119947718-A | Tricyclic aryl derivatives, and compositions and methods thereof | 昂胜医疗科技公司 | 2025-05-06 | — | — | CN | disclosed |
| US-5891875-A | Morpholinyl tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1999-04-06 | — | — | US | disclosed |
| EP-0880558-A1 | COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED INDANE LIBRARIES | ELI LILLY AND COMPANY (US) | 1998-12-02 | — | — | EP | disclosed |
| US-5824678-A | TREATMENT OF PAIN, INFLAMMATION, MIGRAINE, EMESIS; PREPARATION THEREOF | MERCK SHARP & DOHME LTD. (GB) | 1998-10-20 | — | — | US | disclosed |
| EP-0825164-A2 | Scavenger assisted combinatorial process for preparing libraries of amides, carbamates and sulfonamides | ELI LILLY AND COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1997026300-A1 | COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED INDANE LIBRARIES | ELI LILLY AND COMPANY (US) | 1997-07-24 | — | — | WO | disclosed |
| US-5612337-A | ANALGESIC COMPOUNDS FOR PRODRUGS | MERCK SHARP & DOHME LIMITED (GB) | 1997-03-18 | — | — | US | disclosed |
| US-5610159-A | N-oxides of morpholine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 1997-03-11 | — | — | US | disclosed |
| EP-0737192-A1 | SUBSTITUTED MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018124-A1 | SUBSTITUTED MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583851-B2 | Heteroaryl-substituted pyrazine derivatives as pesticides | CBR3, CYCS, CWC15 | CES2 122/4885VNN1 2902/4885RXRA 3466/4885 |
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | PIK3R5, PIK3R4, PIK3R1 | CES2 2908/4885VNN1 3250/4885RXRA 2143/4885 |
| US-20250171444-A1 | PI3Ka INHIBITORS | PIK3CA, PIK3C2A, PIK3R5 | CES2 3305/4885VNN1 4304/4885RXRA 2899/4885 |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RORB, ROR1, RORA | CES2 1588/4885VNN1 4430/4885RXRA 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.